Pharmaceutical News

RSS

Neutralization approach appears to prevent proliferative vitreoretinopathy

Proliferative vitreoretinopathy (PVR), or the formation of scar tissue within the eye, is a serious, sight-threatening complication in patients recovering surgical repair of retinal detachment. A new study conducted by investigators at the Schepens Eye Research Institute, the Department of Ophthalmology at Harvard Medical School, and the Massachusetts Eye and Ear Infirmary in Boston, published in the December issue of the American Journal of Pathology, suggests that a cocktail containing reagents to neutralize a relatively small subset of vitreal growth factors and cytokines may be an effective treatment.

31 Oct 2011

Renowned obstetrician receives March of Dimes 2011 Agnes Higgins award

A highly renowned obstetrician, professor and researcher who showed that babies born to obese and diabetic women have a higher risk of becoming overweight and developing diabetes or other metabolic health problems later in life, received the March of Dimes 2011 Agnes Higgins award for outstanding achievement in the field of maternal-fetal nutrition.

31 Oct 2011

New library for development of targeted cancer drugs

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

31 Oct 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

VUMC doctors to begin statin drug screening for rare genetic variation

Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

NYUCN to study 'Test and Linkage to Care Among Injecting Drug Users Kenya'

New York University College of Nursing (NYUCN) received a five-year, $4,161,665.00 grant from the National Institute of Health's National Institute on Drug Abuse (NIH/NIDA) to research "Test and Linkage to Care Among Injecting Drug Users (TLC_IDU) Kenya."

29 Oct 2011

Massachusetts court awards injunction preventing Watson from selling Amphastar's generic LOVENOX

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX.

29 Oct 2011

White Smile Global introduces new at-home, foaming teeth whitening product

White Smile Global Inc. introduces the White Smile Complete Oral Foam featuring Dual Oxygen-Infused Technology.

29 Oct 2011

MEDA files marketing authorization application for Dymista in Europe

The marketing authorization application for Dymista (a novel formulation of azelastine hydrochloride and fluticasone propionate) has been filed in Europe. The application uses a decentralized procedure and the reference member state is Germany.

29 Oct 2011

Preventive use of ACZ may reduce risk of severe high altitude illness

Measuring specific, exercise-related responses can help physicians determine who may be more at risk for severe high altitude illness (SHAI), according to a study conducted by researchers in France. The researchers also found that taking acetazolamide (ACZ), a drug frequently prescribed to prevent altitude illness, can reduce some of the risk factors associated with SHAI.

29 Oct 2011

EC approves Lilly's ALIMTA as continuation maintenance therapy for NSCLC

Eli Lilly and Company announced today that the European Commission has granted approval for the use of ALIMTA (pemetrexed for injection) as a single agent for continuation maintenance therapy in patients with a particular type of lung cancer, called advanced nonsquamous non-small cell lung cancer

29 Oct 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

New vaccine to eradicate meningitis

Outbreaks of meningitis can quickly reach epidemic proportions across a number of African countries, afflicting tens of thousands of people. Now a new vaccine appears capable of completely eradicating the disease.

28 Oct 2011

GAVI Alliance brings life-saving pneumococcal vaccine to Nicaragua

In this post in PBS NewsHour's blog "The Rundown," senior correspondent Ray Suarez reports on his time in Nicaragua with the NewsHour's global health unit for the national rollout of a pneumococcal pneumonia immunization campaign.

28 Oct 2011

Researchers announce new method to build important heparin drug

Robert Linhardt is working to forever change the way some of the most widely used drugs in the world are manufactured. Today, in the journal Science, he and his partner in the research, Jian Liu, have announced an important step toward making this a reality. The discovery appears in the October 28, 2011 edition of the journal Science in a paper titled "chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparins."

28 Oct 2011

Swapping IV medications with oral equivalents may save millions

Switching hospitalized patients able to take medication by mouth from intravenous to pill forms of the same drugs could safely save millions of dollars a year, new Johns Hopkins research suggests.

28 Oct 2011

Virtual platform for intellectual property sharing aims to speed development of drug treatments

"The World Intellectual Property Organization (WIPO) launched a consortium on Wednesday that would allow the public and private sector to share intellectual property to promote the development of new drugs to treat diseases such as malaria," Reuters reports.

28 Oct 2011

Fasudil drug shows promise against cerebral cavernous malformation

A drug treatment has been proven to prevent lesions from cerebral cavernous malformation — a brain blood vessel abnormality that can cause bleeding, epilepsy and stroke — for the first time in a new study.

28 Oct 2011

RA drug reduces kidney cyst growth in ADPKD mouse model

Scientists at UC Santa Barbara have discovered that patients with an inherited kidney disease may be helped by a drug that is currently available for other uses.

28 Oct 2011